Sargent Investment Group LLC Invests $256,000 in Insulet Co. (NASDAQ:PODD)

Sargent Investment Group LLC acquired a new stake in Insulet Co. (NASDAQ:PODD - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 955 shares of the medical instruments supplier's stock, valued at approximately $256,000.

Several other hedge funds and other institutional investors have also made changes to their positions in PODD. Blue Trust Inc. raised its stake in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after buying an additional 58 shares in the last quarter. Venturi Wealth Management LLC grew its holdings in Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock worth $36,000 after acquiring an additional 133 shares during the period. TD Private Client Wealth LLC raised its position in Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after acquiring an additional 56 shares in the last quarter. Friedenthal Financial acquired a new stake in Insulet in the 4th quarter valued at about $57,000. Finally, Versant Capital Management Inc boosted its position in shares of Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier's stock valued at $80,000 after purchasing an additional 157 shares in the last quarter.

Insulet Stock Down 1.6 %

Shares of PODD stock traded down $4.59 during trading on Friday, hitting $283.08. 399,688 shares of the company were exchanged, compared to its average volume of 522,338. The firm has a market capitalization of $19.86 billion, a price-to-earnings ratio of 48.47, a P/E/G ratio of 3.61 and a beta of 1.23. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The business's 50-day simple moving average is $270.27 and its 200 day simple moving average is $241.25. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, beating the consensus estimate of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The business had revenue of $543.90 million for the quarter, compared to analysts' expectations of $518.50 million. During the same period in the previous year, the company posted $0.71 EPS. As a group, analysts forecast that Insulet Co. will post 3.22 EPS for the current fiscal year.

Insider Buying and Selling at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company's stock, valued at $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Lauren Budden sold 915 shares of the business's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company's stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on PODD. Citigroup boosted their target price on shares of Insulet from $283.00 to $310.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Raymond James increased their price objective on Insulet from $213.00 to $260.00 and gave the company an "outperform" rating in a research report on Monday, October 14th. Barclays raised their price objective on Insulet from $220.00 to $234.00 and gave the stock an "equal weight" rating in a research note on Monday, November 11th. TD Cowen upped their target price on Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a report on Friday, January 3rd. Finally, BTIG Research lifted their price target on Insulet from $260.00 to $270.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $277.13.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.